We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
Fields »
 

Field

Term
Gene name

Class

Subclass

Chromosome

External id

In atlas

Reliability

Reliability

Reliability

Validation

Method

Validation

Method

Validation

Method

Validation

Location

Searches

Tissue

Cell type

Expression

Tissue

Specificity

Cell line

Specificity

Cancer

Specificity

Tissue

Detectable

Cell line

Detectable

Cancer

Detectable

Cancer

Prognosis

Category

Score

Score

Score

Antibodies

Column

 
 
ABOUT
HELP
BLOG
  • THE HUMAN PROTEOME
  • THE HUMAN TISSUES
  • THE HUMAN CELL
  • HUMAN PATHOLOGY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
    • NEWS
    • BLOG
    • EVENTS
    • PRESS ROOM
    • LEARN
    • DICTIONARY
    • METHODS
    • CELL LINES
  • THE PROJECT
  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • PUBLICATION DATA
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • LINKS
  • CONTACT
  • TECHNICAL DATA
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • DOWNLOADABLE DATA
  • HELP & FAQ
  • LICENCE & CITATION
  • PRIVACY STATEMENT
  • RELEASE HISTORY
BCL11A
  • TISSUE

  • premium

    CELL

  • PATHOLOGY

PATHOLOGY ATLAS

GENE/PROTEIN

Antibody validation

Dictionary

Level of antibody staining/expression





High
Medium
Low
Not detected

GENERAL INFORMATION

Gene namei

Gene name according to HGNC.

BCL11A

Gene descriptioni

Gene description according to HGNC.

B-cell CLL/lymphoma 11A (zinc finger protein)

Protein classi

Protein class the gene product belongs to according to selected gene lists. List of protein classes.

Cancer-related genes
Disease related genes
Plasma proteins
Predicted intracellular proteins
Transcription factors

Predicted localizationi

Protein localization predicted from several bioinformatic algorithms.

Read more

Intracellular

Number of transcriptsi

Number of protein-coding transcribed from this gene as defined by Ensembl.

7
SHOW MORE

HUMAN PROTEIN ATLAS INFORMATION

RNA categoryi

RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.

TCGA (cancer tissue):Mixed
HPA (cell line):Cell line enhanced (Daudi, MOLT-4, REH, U-698)
HPA (normal tissue):Tissue enhanced (skin)

Protein evidencei

Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.

Evidence at protein level

Protein expression
normal tissuei

A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.

"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.

Read more

Nuclear expression mainly in neuronal cells, squamous epithelial cells and immune cells.

ANTIBODY IHC RELIABILITY

Data reliability
descriptioni

Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.

Antibody staining mainly consistent with RNA expression data.

Reliability scorei

Reliability score (score description), divided into Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between the staining pattern of one antibody or several antibodies with RNA-seq data and available gene/protein characterization data.

Read more

Approved based on 2 antibodies.
HPA029003 , CAB014891
SHOW MORE

PROGNOSTIC SUMMARYi

Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.

Gene product is not prognostic.
Show all

RNA EXPRESSION OVERVIEWi

RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).

TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name.

Read more
RNA cancer category: Mixed

PROTEIN EXPRESSIONi

Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

For histological reference, visit the histological dictionary.

Colorectal cancer
Breast cancer
Prostate cancer
Lung cancer
Liver cancer

STAINING SUMMARYi

For each cancer, the fraction of samples with protein expression level high, medium, low, or not detected are provided by the blue-scale color-coding (as described by the color-coding scale in the box to the left). The length of the bar represents the number of patient samples analyzed (max=12 patients). The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies. The mouse-over function displays additional data for the features in the staining summary view.

Next to the cancer staining data, the protein expression data of normal tissues or specific cell types corresponding to each cancer are shown and protein expression levels are indicated by the blue-scale color coding.

HPA029003
CAB014891

Cancer

Cancer staining

Protein
expression of
normal tissue

Breast cancer
 
Carcinoid
 
Cervical cancer
 
 
Colorectal cancer
 
 
Endometrial cancer
 
 
Glioma
 
Head and neck cancer
 
 
Liver cancer
 
 
Lung cancer
 
 
Lymphoma
 
 
 

Cancer

Cancer staining

Protein
expression of
normal tissue

Melanoma
 
Ovarian cancer
 
Pancreatic cancer
 
Prostate cancer
 
Renal cancer
 
Skin cancer
 
Stomach cancer
 
 
Testis cancer
 
Thyroid cancer
 
Urothelial cancer
 

Staining summaryi

A manually written summary of the overall protein expression pattern across the analyzed cancer tissues.

Few lymphomas, cervical cancers along with occasional colorectal, skin, head and neck cancers showed moderate nuclear positivity. Other cancer tissues were generally negative.

Cancer

Cancer staining

Protein
expression of
normal tissue

Breast cancer
 
Carcinoid
 
Cervical cancer
 
 
Colorectal cancer
 
 
Endometrial cancer
 
 
Glioma
 
Head and neck cancer
 
 
Liver cancer
 
 
Lung cancer
 
 
Lymphoma
 
 
 

Cancer

Cancer staining

Protein
expression of
normal tissue

Melanoma
 
Ovarian cancer
 
Pancreatic cancer
 
Prostate cancer
 
Renal cancer
 
Skin cancer
 
Stomach cancer
 
 
Testis cancer
 
Thyroid cancer
 
Urothelial cancer
 

Staining summaryi

A manually written summary of the overall protein expression pattern across the analyzed cancer tissues.

Cancer tissues showed moderate to strong cytoplasmic and nuclear immunoreactivity. Many liver and prostate cancers were weakly stained or negative.

GENE INFORMATIONi

Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.

Gene name

BCL11A (HGNC Symbol)

Synonyms

BCL11A-L, BCL11A-S, BCL11A-XL, CTIP1, EVI9, HBFQTL5, ZNF856

Description

B-cell CLL/lymphoma 11A (zinc finger protein) (HGNC Symbol)

Entrez gene summary

This gene encodes a C2H2 type zinc-finger protein by its similarity to the mouse Bcl11a/Evi9 protein. The corresponding mouse gene is a common site of retroviral integration in myeloid leukemia, and may function as a leukemia disease gene, in part, through its interaction with BCL6. During hematopoietic cell differentiation, this gene is down-regulated. It is possibly involved in lymphoma pathogenesis since translocations associated with B-cell malignancies also deregulates its expression. Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Chromosome

2

Cytoband

p16.1

Chromosome location (bp)

60451167 - 60553567

Protein evidence

Evidence at protein level (all genes)

Ensembl

ENSG00000119866 (version 83.38)

Entrez gene

53335

UniProt

Q9H165 (UniProt - Evidence at protein level)

neXtProt

NX_Q9H165

Antibodypedia

BCL11A antibodies

PROTEIN BROWSERi

The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.

At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.

Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50) (read more).

If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.

Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.

BCL11A-001
BCL11A-002
BCL11A-003
BCL11A-004
BCL11A-006
BCL11A-007
BCL11A-013

PROTEIN INFORMATIONi

The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.

The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.

The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.

The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.

Splice variant

UniProt

Protein class

Gene ontology

Length & mass

Signal peptide
(predicted)

Transmembrane regions
(predicted)

BCL11A-001
ENSP00000338774
ENST00000335712
Q9H165 [Direct mapping]
B-cell lymphoma/leukemia 11A
D6W5D9 [Target identity:100%; Query identity:100%]
B-cell CLL/lymphoma 11A (Zinc finger protein), isoform CRA_b; BCL11A B-cell CLL/lymphoma 11A (Zinc finger protein) isoform 1
Show all
Predicted intracellular proteins
Plasma proteins
Transcription factors
   Zinc-coordinating DNA-binding domains
Cancer-related genes
   Candidate cancer biomarkers
   COSMIC somatic mutations in cancer genes
   COSMIC Somatic Mutations
   COSMIC Translocations
Disease related genes
Protein evidence (Kim et al 2014)
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter]
GO:0000978 [RNA polymerase II core promoter proximal region sequence-specific DNA binding]
GO:0001078 [transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding]
GO:0003714 [transcription corepressor activity]
GO:0005515 [protein binding]
GO:0005634 [nucleus]
GO:0005654 [nucleoplasm]
GO:0005737 [cytoplasm]
GO:0006351 [transcription, DNA-templated]
GO:0007165 [signal transduction]
GO:0010629 [negative regulation of gene expression]
GO:0010976 [positive regulation of neuron projection development]
GO:0010977 [negative regulation of neuron projection development]
GO:0016925 [protein sumoylation]
GO:0030183 [B cell differentiation]
GO:0030217 [T cell differentiation]
GO:0030517 [negative regulation of axon extension]
GO:0032463 [negative regulation of protein homooligomerization]
GO:0042803 [protein homodimerization activity]
GO:0045944 [positive regulation of transcription from RNA polymerase II promoter]
GO:0046872 [metal ion binding]
GO:0046982 [protein heterodimerization activity]
GO:0048671 [negative regulation of collateral sprouting]
GO:0048672 [positive regulation of collateral sprouting]
GO:0050773 [regulation of dendrite development]
GO:2000171 [negative regulation of dendrite development]
Show all
835 aa
91.2 kDa
No 0
BCL11A-002
ENSP00000349300
ENST00000356842
Q9H165 [Direct mapping]
B-cell lymphoma/leukemia 11A
D9YZV9 [Target identity:100%; Query identity:100%]
B-cell CLL/lymphoma 11A (Zinc finger protein) isoform 2; B-cell CLL/lymphoma 11A (Zinc finger protein), isoform CRA_c
Show all
Predicted intracellular proteins
Plasma proteins
Transcription factors
   Zinc-coordinating DNA-binding domains
Cancer-related genes
   Candidate cancer biomarkers
   COSMIC somatic mutations in cancer genes
   COSMIC Somatic Mutations
   COSMIC Translocations
Disease related genes
Protein evidence (Kim et al 2014)
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter]
GO:0000978 [RNA polymerase II core promoter proximal region sequence-specific DNA binding]
GO:0001078 [transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding]
GO:0005515 [protein binding]
GO:0005634 [nucleus]
GO:0005654 [nucleoplasm]
GO:0005737 [cytoplasm]
GO:0006351 [transcription, DNA-templated]
GO:0007165 [signal transduction]
GO:0010976 [positive regulation of neuron projection development]
GO:0010977 [negative regulation of neuron projection development]
GO:0016925 [protein sumoylation]
GO:0030517 [negative regulation of axon extension]
GO:0032463 [negative regulation of protein homooligomerization]
GO:0042803 [protein homodimerization activity]
GO:0045944 [positive regulation of transcription from RNA polymerase II promoter]
GO:0046872 [metal ion binding]
GO:0046982 [protein heterodimerization activity]
GO:0048671 [negative regulation of collateral sprouting]
GO:0048672 [positive regulation of collateral sprouting]
GO:0050773 [regulation of dendrite development]
GO:2000171 [negative regulation of dendrite development]
Show all
773 aa
83.9 kDa
No 0
BCL11A-003
ENSP00000352648
ENST00000359629
Q9H165 [Direct mapping]
B-cell lymphoma/leukemia 11A
Show all
Predicted intracellular proteins
Plasma proteins
Transcription factors
   Zinc-coordinating DNA-binding domains
Cancer-related genes
   Candidate cancer biomarkers
   COSMIC somatic mutations in cancer genes
   COSMIC Somatic Mutations
   COSMIC Translocations
Disease related genes
Protein evidence (Kim et al 2014)
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter]
GO:0000978 [RNA polymerase II core promoter proximal region sequence-specific DNA binding]
GO:0001078 [transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding]
GO:0005515 [protein binding]
GO:0005634 [nucleus]
GO:0005654 [nucleoplasm]
GO:0005737 [cytoplasm]
GO:0006351 [transcription, DNA-templated]
GO:0007165 [signal transduction]
GO:0010976 [positive regulation of neuron projection development]
GO:0010977 [negative regulation of neuron projection development]
GO:0016925 [protein sumoylation]
GO:0030517 [negative regulation of axon extension]
GO:0032463 [negative regulation of protein homooligomerization]
GO:0042803 [protein homodimerization activity]
GO:0045944 [positive regulation of transcription from RNA polymerase II promoter]
GO:0046872 [metal ion binding]
GO:0046982 [protein heterodimerization activity]
GO:0048671 [negative regulation of collateral sprouting]
GO:0048672 [positive regulation of collateral sprouting]
GO:0050773 [regulation of dendrite development]
GO:2000171 [negative regulation of dendrite development]
Show all
243 aa
26.9 kDa
No 0
BCL11A-004
ENSP00000487844
ENST00000409351
Q66LN6 [Target identity:100%; Query identity:100%]
B-cell lymphoma/leukaemia 11A extra-short form
Show all
Predicted intracellular proteins
Cancer-related genes
   COSMIC somatic mutations in cancer genes
   COSMIC Somatic Mutations
   COSMIC Translocations
Protein evidence (Ezkurdia et al 2014)
Show all
142 aa
15.7 kDa
No 0
BCL11A-006
ENSP00000351307
ENST00000358510
Q9H165 [Direct mapping]
B-cell lymphoma/leukemia 11A
Show all
Predicted intracellular proteins
Plasma proteins
Transcription factors
   Zinc-coordinating DNA-binding domains
Cancer-related genes
   Candidate cancer biomarkers
   COSMIC somatic mutations in cancer genes
   COSMIC Somatic Mutations
   COSMIC Translocations
Disease related genes
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter]
GO:0000978 [RNA polymerase II core promoter proximal region sequence-specific DNA binding]
GO:0001078 [transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding]
GO:0005515 [protein binding]
GO:0005634 [nucleus]
GO:0005654 [nucleoplasm]
GO:0005737 [cytoplasm]
GO:0006351 [transcription, DNA-templated]
GO:0007165 [signal transduction]
GO:0010976 [positive regulation of neuron projection development]
GO:0010977 [negative regulation of neuron projection development]
GO:0016925 [protein sumoylation]
GO:0030517 [negative regulation of axon extension]
GO:0032463 [negative regulation of protein homooligomerization]
GO:0042803 [protein homodimerization activity]
GO:0045944 [positive regulation of transcription from RNA polymerase II promoter]
GO:0046872 [metal ion binding]
GO:0046982 [protein heterodimerization activity]
GO:0048671 [negative regulation of collateral sprouting]
GO:0048672 [positive regulation of collateral sprouting]
GO:0050773 [regulation of dendrite development]
GO:2000171 [negative regulation of dendrite development]
Show all
801 aa
87.6 kDa
No 0
BCL11A-007
ENSP00000488390
ENST00000489516
Predicted intracellular proteins
Cancer-related genes
   COSMIC somatic mutations in cancer genes
   COSMIC Somatic Mutations
   COSMIC Translocations
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0046872 [metal ion binding]
Show all
191 aa
21.1 kDa
No 0
BCL11A-013
ENSP00000488636
ENST00000479026
Predicted intracellular proteins
Cancer-related genes
   COSMIC somatic mutations in cancer genes
   COSMIC Somatic Mutations
   COSMIC Translocations
Protein evidence (Ezkurdia et al 2014)
Show all
17 aa
2 kDa
No 0

Contact

  • BLOG
  • PRESS ROOM
  • contact@proteinatlas.org

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • DOWNLOADABLE DATA

The Human Protein Atlas

  • ANTIBODY AVAILABILITY
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg foundation.